ACADIA Pharmaceuticals is a commercial-stage biopharmaceutical company focused on neurological and rare diseases, with two FDA-approved first-in-class drugs. NUPLAZID (pimavanserin) is the only approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, a condition affecting roughly half of the approximately 1 million U.S. Parkinson's patients. NUPLAZID's key clinical advantage is that it treats psychotic symptoms without blocking dopamine receptors, avoiding the motor function deterioration caused by off-label generic antipsychotics. DAYBUE (trofinetide) is the only approved treatment for Rett syndrome, a severe neurological disorder affecting an estimated 6,000 diagnosed patients in the U.S. ACADIA sells both products almost entirely in the U.S. through specialty pharmacies and distributors, promoting to neurologists, psychiatrists, and increasingly primary care physicians. Both products carry meaningful gross-to-net adjustments driven by government rebates under Medicaid and Medicare. ACADIA outsources manufacturing and distribution, so its primary costs are SG&A and R&D. The most important pipeline asset is remlifanserin, a next-generation version of NUPLAZID's mechanism targeting Alzheimer's disease psychosis and Lewy body dementia psychosis, with Phase 2 data expected in late 2026. ACADIA's stated goals are $1B in annual NUPLAZID net sales and $700M in global DAYBUE net sales by 2028, with longer-term growth expected from the broader pipeline.